Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about XNCR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| XmAb942 | Ulcerative Colitis (UC) | Phase 1/2 · NCT06619990 | Recruiting |
| Izuralimab (XmAb23104) | Sarcoma | Phase 2 · NCT05879185 | Terminated |
| Vudalimab (XmAb20717) | Biliary Tract Cancer | Phase 2 · NCT05297903 | Completed |
| Plamotamab (XmAb13676) | Diffuse Large-cell B-cell Lymphoma | Phase 2 · NCT05328102 | Terminated |
| Tidutamab (XmAb18087) | Merkel Cell Carcinoma | Phase 1/2 · NCT04590781 | Terminated |
| Obexelimab (XmAb5871) | Systemic Lupus Erythematosus | Phase 2 · NCT02725515 | Completed |
| XmAb27564 | Psoriasis | Phase 1 · NCT06005792 | Terminated |
| XmAb412 Monoclonal Bispecific Antibody | Not Applicable - Healthy Adult Participants | Phase 1 · NCT07713485 | Recruiting |
| Anti-CLDN6/CD3 Bispecific Antibody XmAb541 | Ovarian Cancer | Phase 1 · NCT07593092 | Recruiting |
| XmAb657 | Healthy | Phase 1 · NCT07284797 | Recruiting |
| IL-12-Fc Fusion Protein XmAb662 | Solid Tumors | Phase 1 · NCT05996445 | Terminated |
| XmAb7195 | Healthy Volunteers | Phase 1 · NCT02881853 | Completed |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808 | Ovarian Cancer | Phase 1 · NCT07593092 | Recruiting |
| Anti-ENPP3/Anti-CD3 Bispecific Antibody XmAb819 | Clear Cell Renal Cell Carcinoma | Phase 1 · NCT05433142 | Recruiting |
| Anti-CD30 Monoclonal Antibody XmAb2513 | Hodgkin Lymphoma | Phase 1 · NCT00606645 | Completed |
| Pavunalimab (XmAb22841) | Metastatic Melanoma | Phase 1 · NCT05695898 | Terminated |
Also used in these trials (approved or third-party drugs, not XNCR's own candidates): Lenalidomide, Regorafenib, Tafasitamab (XmAb5574), Ipilimumab, Abiraterone Acetate, Pembrolizumab, Enzalutamide, Docetaxel Anhydrous.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
XNCR holds $555.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $26.5M/quarter from operations, an estimated runway of 62.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XNCR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 10,816,417 | 14.41% | 2026-09-30 |
| PRIMECAP MANAGEMENT CO/CA/ | Institution (13G, 5%+) | 9,879,855 | 13.17% | 2026-09-30 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 7,133,720 | 9.51% | 2025-12-31 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 4,736,739 | 6.31% | 2026-03-23 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 4,507,254 | 6.01% | 2025-12-31 |
| The Toronto-Dominion Bank | Institution (13G, 5%+) | 3,871,296 | 5.16% | 2026-09-30 |
| Bassil I Dahiyat PRESIDENT & CEO, Director · +583,748 options |
Insider | 546,316 | 0.73% | 2026-03-05 |
| John R Desjarlais SR. VICE PRESIDENT & CSO · +149,440 options |
Insider | 263,831 | 0.35% | 2026-03-05 |
| Celia Eckert SVP, GENERAL COUNSEL · +112,080 options |
Insider | 76,918 | 0.10% | 2026-03-05 |
| Bart Jan Cornelissen SR. VICE PRESIDENT & CFO · +116,750 options |
Insider | 65,798 | 0.09% | 2026-11-11 |
| Nancy Valente EVP, Chief Development Officer |
Insider | 49,169 | 0.07% | 2025-05-02 |
| Barbara Klencke Director · +47,976 options |
Insider | 29,974 | 0.04% | 2026-06-16 |
Share count 75,039,689 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XNCR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →